Dengue virus serotype 4 pre-membrane protein and envelope protein (DENV-4 prM/E)

The dengue virus serotype 4 pre-membrane protein and envelope glycoprotein (DENV-4 prM/E) are critical structural proteins on the surface of the dengue virus particle. The envelope (E) protein is responsible for receptor binding, viral attachment to host cells, and mediating fusion between viral and host membranes, enabling the viral genome to enter the host cytoplasm. The pre-membrane (prM) protein acts as a chaperone during viral maturation, protecting the fusion loop of the E protein until the virus is ready to infect new cells. The E protein consists of three domains (EDI, EDII, EDIII); EDIII contains key epitopes for neutralizing antibodies and is a primary target of the humoral immune response. Vaccine candidates and diagnostic reagents frequently use recombinant DENV-4 E and prM proteins to induce or monitor protective immunity. Several monoclonal antibodies targeting the DENV-4 E protein are highly potent, but the phenomenon of antibody-dependent enhancement presents challenges for vaccine and therapeutic development. Structurally, E and prM are viral glycoproteins, assembled as dimers or trimers on the virion surface, and play essential roles in dengue virus infection, immune response, and disease pathogenesis.

Other names

DENV-4 prM/E glycoproteinDengue virus type 4 prM and E proteinsDENV4 envelope glycoproteinDENV4 E proteinDengue virus serotype 4 envelope protein

Neutralization (monoclonal antibodies bind E protein, block membrane fusion, prevent cell entry); Vaccine-induced immunity (prM/E used as antigens to elicit protective antibody responses); Inhibition of viral maturation (experimental strategies to block prM-mediated maturation)